Research progress on HIV-1 structural proteins and antiviral therapies Authors: Huihan Wang, Jinsong Yuan, Hong Wang Published: 2026 ABSTRACT Human Immunodeficiency Virus (HIV), including HIV-1 and HIV-2, is a retrovirus that causes Acquired Immunodeficiency Syndrome (AIDS). HIV primarily targets the human immune system, especially CD4+ T lymphocytes, leading to progressive immune system dysfunction and rendering patients susceptible to severe opportunistic infections and malignancies. HIV-1 accounts for the majority of global HIV infections, and most structural, mechanistic, and therapeutic studies have been conducted in HIV-1 systems. The structural proteins Gag, Pol, and Env of HIV-1 play a pivotal role in the viral life cycle, making their functional mechanisms and inhibitor development key to advancing anti-AIDS drug research. This article provides a narrative review of recent advances in antiviral drug development targeting these proteins and discusses future design strategies. It offers critical insights for accelerating next-generation anti-HIV drug development and advancing global AIDS control efforts. Introduction Human immunodeficiency virus (HIV), a retrovirus that includes HIV-1 and HIV-2, relies on the coordinated activity of various virally encoded proteins to complete its replication cycle. These components are essential not only for virion assembly and release but also play critical roles in mediating virus–host interactions (1). Because HIV-1 accounts for the majority of global HIV infections and most structural, mechanistic, and therapeutic studies have been conducted in HIV-1 systems, this review mainly focuses on HIV-1. The HIV-1 genome encodes nine genes, which include structural proteins (Gag, Pol, Env), accessory proteins (Vif, Vpu, Vpr) and regulatory proteins (Rev, Tat, Nef) (2). Among these, the structural proteins Gag, Pol and Env are particularly crucial. Gag and Pol are responsible for the assembly of new virions and the processing of viral proteins, while Env facilitates the virus’s entry into host cells by interacting with the host cell receptors. These proteins are not only indispensable for the virus’s replication cycle but also present attractive targets for antiviral interventions, as disrupting their functions can prevent viral assembly, maturation, and entry. This article is intended as a narrative review focusing on the structure and function of HIV-1 structural proteins, current antiviral drug development targeting these proteins, and potential directions for future drug design. Structural and functional roles of HIV-1 structural proteins Gag protein Gag (Group-specific antigen) is an HIV-1 polyprotein essential for viral structure and infectivity. The Gag precursor (p55) consists of the matrix protein (MA/p17), capsid protein (CA/p24), nucleocapsid protein (NC/p7), and the p6 domain, each of which performs distinct functions (3) (Figure 1A). Gag, Gag-Pol and Env polyprotein processing. (A) Proteolytic processing starts at the SP1–NC junction at the RQA|NFLG cleavage site, then proceeds to the MA–CA and SP2–p6 junctions at SQNY|PIV and PGNF|LQS, respectively. Subsequently, the spacer peptides SP1 and SP2 are trimmed from CA and NC at ARVL|AEA and RQAN|FLG. (B) The HIV-1 Gag–Pol polyprotein is generated by a programed −1 ribosomal frameshift at the NC/SP1 junction, placing the p6 region into an alternative reading frame to form the transframe domain (TF/p6*) upstream of Pol. Maturation is initiated by auto-processing at the TF|PR site (SFNF|PQIT), catalyzed by the weakly active protease precursor. This cleavage separates the N-terminal Gag-derived segment (MA–CA–SP1–NC–SP2–TF) from the Pol enzymes (PR–RT–RNase H–IN), releasing PR to drive subsequent ordered processing. (C) The Env protein is initially synthesized as a precursor, gp160 (a glycoprotein with an apparent molecular weight of 160 kDa), which undergoes processing by Furin. Subsequently, gp160 is cleaved by a cellular furin-like protease into two subunits: the receptor-binding subunit gp120 and the fusion subunit gp41. MA is composed of an N-terminal globular head and a C-terminal tail (4). Functionally, MA directs Gag-Pol and PR55Gag to the plasma membrane (3). This process is governed by two key chemical signals: myristoylation and interaction with the plasma membrane-specific phospholipid phosphatidylinositol-4,5-bisphosphate (PIP2) (5). During viral entry, myristoylation occurs first, in which an N-myristoyltransferase catalyzes the formation of a covalent bond between myristic acid and the MA N-terminal domain (4). This modification increases the affinity of MA for the plasma membrane, helping to target the protein to membrane structures. The second signal involves electrostatic interactions between basic residues (HBR) in MA and negatively charged PIP2 in the plasma membrane (5). Following myristic acid exposure, insertion into the lipid bilayer occurs. During the transition from sequestration to exposure, the PIP2 recognition site (30KLKH34) sequesters PIP2 fatty acids into a hydrophobic pocket. The interactions between the plasma membrane and myristic acid subsequently promote the formation of a bidirectional lipid bilayer (6, 7). In mature virions, HIV-1 capsid protein oligomerizes to form a protective shell around the viral RNA and core-associated proteins (8). CA consists of two domains: the N-terminal domain (CANTD1-149) and the C-terminal domain (CACTD150-231), connected by a flexible linker (9). The capsid encloses viral RNA and core proteins, shielding them from antiviral factors and cellular sensors of innate immunity (10, 11). Beyond its structural role, CA participates in multiple stages of the viral replication cycle, including reverse transcription (RT), cytoplasmic transport via microtubules, uncoating of the viral pre-integration complex, nuclear import, integration, and viral assembly (12, 13). Comprising 55 amino acids, NC contains two highly conserved zinc finger motifs (Cys-X2-Cys-X4-His-X4-Cys) (14). It is responsible for the specific recognition and selective packaging of the viral packaging signal (Psi, Ψ) located in the 5′-leader region of the viral genome, enabling the incorporation of two copies of genomic RNA into nascent virions amid a vast excess of cellular RNA (15). Following viral maturation and release from the cell, NCp7 is liberated through proteolytic cleavage of the Gag polyprotein by the viral protease (16). p6 domain contains PTAP and YPXL protein interaction motifs, which recruit the host endosomal sorting complex required for transport (ESCRT) to facilitate the budding of immature virions from the host cell (17). The YPXL (Tyr-Pro-X-Leu) motif binds to the cellular factor ALG-2-interacting protein X (ALIX), while PTAP interacts with the host protein tumor susceptibility gene 101 (TSG101) (18). The four PTAP residues contact the N-terminal ubiquitin E2 variant (UEV) domain of TSG101 (19). Thus, p6 can be regarded as a viral mimic that recruits cellular ESCRT-I machinery in HIV-1 (20). Although earlier studies indicated that the NC domain of the precursor PR55 Gag protein primarily governs genomic RNA selection by recognizing the gag gene initiation sequence and the Ψ packaging signal, recent evidence suggests that the p6 domain also modulates the RNA-binding specificity of PR55 (21). Pol protein The HIV-1 Pol protein is a core functional protein essential for viral replication. The Gag-to-Gag-Pol output from the same full-length viral mRNA is set by a programed ribosomal frameshift (22). Approximately 5–10% of ribosomes initiating translation on the full-length vRNA shift into the −1 reading frame via a programed−1 ribosomal frameshift, resulting in Gag-Pol rather than Gag (23). It is produced by the proteolytic cleavage of the Gag-Pol precursor polyprotein. This multifunctional enzyme consists of three distinct domains: protease (PR), reverse transcriptase (RT) and integrase (IN) (Figure 1B). The PR domain is responsible for cleaving viral polyprotein precursors, the RT domain facilitates the reverse transcription of viral RNA into DNA, and the IN domain catalyzes the integration of the viral DNA into the host genome. Through their coordinated actions, these three domains work together to complete the HIV-1 replication cycle. PR consists of two identical subunits and belongs to the aspartyl protease family. Each subunit contains a conserved catalytic triad, Asp-Thr/Ser-Gly. Following viral maturation, PR precisely recognizes and hydrolyzes specific peptide bonds within precursor proteins. It sequentially cleaves the Gag and Gag-Pol precursors, thereby processing them into mature, functional viral proteins (22). This process is critical for the formation of infectious viral particles, making PR an important target for antiretroviral drug development. RT is a heterodimer consisting of p66 and p51 subunits, derived from the proteolytic processing of the Pol polyprotein precursor. Initial homodimeric p66 molecules undergo conformational rearrangement, where one subunit retains full enzymatic activity while the other (p66’) provides structural support. Subsequent cleavage of the C-terminal RNase H domain in the p66’ subunit yields the 440-amino-acid p51 subunit (22). RT exhibits the canonical “hand” architecture, composed of fingers (residues 1-85, 118-155), palm (86-117, 156-236), thumb (237-318), and connection (319-426) subdomains. Although the p51 subunit shares the same primary domain organization as p66, their distinct spatial arrangements result in an overall asymmetric heterodimeric structure (24).The enzyme engages template/primer substrates via its catalytic triad (D110, D185, D186). The polymerase active site and the RNase H active site within the p66 subunit are spatially separated by approximately 18 base pairs. As a multifunctional enzyme, the p66 subunit possesses both DNA-dependent DNA polymerase activity and RNase H activity. The conserved YMDD motif constitutes a critical part of the catalytic center, responsible for DNA synthesis and subsequent degradation of the RNA template. Notably, the inherent lack of a proofreading function in RT contributes to its high error rate, which is a major factor driving the generation of HIV-1 drug resistance (25). IN is a polynucleotidyl transferase that catalyzes two sequential enzymatic reactions essential for integration: 3’-processing and strand transfer (26). The enzyme is organized into three conserved structural domains: the N-terminal domain (NTD), which binds Zn²+ via an HHCC zinc finger motif (involving His and Cys residues) to form a three-helix bundle; the catalytic core domain (CCD), which adopts an RNase H-like fold and contains the conserved DDE catalytic triad; and the C-terminal domain (CTD), which exhibits an SH3-like fold (27). During the 3’-processing step, IN hydrolytically removes two nucleotides (typically a conserved CA dinucleotide) from each 3’ end of the viral DNA, preparing the termini for integration. It is noteworthy that processing mechanisms can vary among different retroviruses, with some viruses capable of integration without symmetrical processing at both ends (28). In the subsequent strand transfer reaction, IN utilizes the newly exposed 3’-OH groups to cleave the host DNA via an SN2-type mechanism and covalently link the viral DNA ends, resulting in the characteristic 5-base pair duplication of host DNA flanking the integrated provirus (29). The entire catalytic process is dependent on two Mg²+ ions coordinated by the DDE motif. These metal ions participate in activating the nucleophile and stabilizing the reaction transition state, a catalytic mechanism that is highly conserved within the polynucleotidyl transferase superfamily (27, 30). Env protein HIV-1 targets CD4+ T cells, macrophages, and dendritic cells, initiating infection via host cell attachment and membrane fusion—a process primarily driven by its envelope glycoprotein (Env). The Env glycoprotein is initially synthesized as a precursor, gp160, which is subsequently cleaved by a cellular protease into two functional subunits: the surface glycoprotein gp120 and the transmembrane glycoprotein gp41 (Figure 1C). Heterodimers of gp120 and gp41 assemble into a trimeric complex, forming the functional unit for infectivity on the surface of the virion (31, 32). While multiple cellular factors can participate in the initial attachment phase, the specific binding of gp120 to the CD4 receptor on the host cell surface is the crucial step that initiates the infection cascade (31). The binding of gp120 to CD4 induces significant conformational changes within the Env trimer. This structural rearrangement exposes the coreceptor binding site on gp120, allowing it to engage with either the CCR5 or CXCR4 chemokine coreceptor (31). The sequential interaction of gp120 with the primary receptor CD4 and a coreceptor (CCR5 or CXCR4) triggers further major conformational changes in the gp41 subunit. These changes result in the insertion of the gp41 N-terminal fusion peptide into the target cell membrane (33). Finally, gp41 refolds into a highly stable six-helix bundle hairpin structure. This structural transition provides the driving force required for bringing the viral and cellular membranes into close proximity, thereby facilitating their fusion and completing the critical entry step of the viral life cycle (34). Research advances in molecular mechanisms and signaling pathways of HIV-1 protein inhibitors The replication of HIV-1 relies on interactions between various viral proteins and host factors. Inhibitors targeting these proteins have become a core strategy in antiviral therapy. Currently, inhibitors of reverse transcriptase (RT), protease (PR), integrase (IN), and envelope protein (Env) are widely used in clinical practice. The following sections summarize the action targets, molecular mechanisms, and host signaling pathways associated with these inhibitors. Gag inhibitors Bevirimat (BVM), the first maturation inhibitor to enter clinical trials, functions by specifically binding to the CA-SP1 junction region. This interaction stabilizes the immature Gag lattice, thereby inhibiting the maturation of viral particles (35). However, its development was discontinued after the emergence of pre-existing CA-SP1 resistance mutations in a subset of patients during clinical trials (36). GSK-3532795 was designed with structural modifications to improve resilience against such resistance, but its Phase II development was terminated due to insufficient efficacy. Subsequently, GS-CA1 and GS-6207 (Lenacapavir) have demonstrated potent antiviral activity. Among these, Lenacapavir has received FDA approval for clinical use (37) (Table 1). Notably, lenacapavir is particularly important not only because it targets a novel binding site at the capsid multimer interface, but also because its favorable pharmacokinetic profile enables subcutaneous dosing every 6 months, thereby linking capsid-directed inhibition to modern long-acting treatment strategies (38, 39). Table 1Antivirals targeting HIV-1 particle maturation and capsid function.ClassProductsStructure (target pocket/site)Stage of developmentReferences and/or ClinicalTrials.gov registry numbersPIsSaquinavir (SQV)Small-molecule PIApproved (treatment)(128)Darunavir (DRV)HIV-1 protease active siteApproved (standard ART option; usage depends on regimen context)(71); NCT00258557MIsGSK3640254Gag CA–SP1 (maturation cleavage region)Phase 2b (reported)(129); NCT04900038;NCT04493216GSK2838232Gag CA–SP1Phase 2a (POC reported)(130); NCT03045861GSK3532795Gag CA–SP1Phase 2b (reported; development limited by tolerability in studies)NCT02415595Bevirimat (BVM)Gag maturation (CA–SP1 region)Phase 2 (historical; not advanced)NCT01097070CAIsLenacapavir for treatment (HTE/MDR HIV-1)Capsid (CA) multimer interface pocketApproved (treatment)(75); NCT04150068Lenacapavir for PrEPCapsid (CA) pocketPhase 3 completed; regulatory adoption documented in public health guidanceNCT04994509, NCT04925752;(85, 131)Once-yearly LenacapaviCapsid (CA) pocketPhase 1 PK/safety published; Phase 3 registered (PURPOSE 365)(131); NCT07047716Once-weekly oral ISL/LEN (islatravir + lenacapavir)NRTTI + capsid inhibitor combinationPhase 2 (48-week results reported)(132); NCT05052996Once-weekly oral ISL/LEN (fixed-dose switch; Phase 3)NRTTI + capsid inhibitor combinationPhase 3 (registered)NCT06630299 Antivirals targeting HIV-1 particle maturation and capsid function. Pol inhibitors Reverse transcriptase is the key enzyme responsible for converting the HIV-1 RNA genome into cDNA. Its inhibitors are broadly categorized into nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). Nucleoside reverse transcriptase inhibitors NRTIs were the first class of drugs approved to treat HIV-1. Resistance to them mainly arises from the high error rate of HIV reverse transcriptase (RT) during replication. The key resistance mechanisms involve either excision, where a mutated RT removes an incorporated NRTI, or discrimination, where mutations alter the dNTP-binding pocket to selectively block NRTI-triphosphate incorporation (4, 40). These mutations typically occur in or near the dNTP binding site, disrupting drug binding or enhancing excision (40). Clinically used NRTIs fall into two categories. The first includes nucleoside analogs such as zidovudine (AZT) and lamivudine (3TC), which require intracellular phosphorylation to become active. The second includes nucleotide analogs like tenofovir (TFV), which are usually given as prodrugs to improve cellular uptake (25). AZT became the first approved HIV-1 drug in 1987. To date, eight NRTIs have been approved for clinical use, with their efficacy heavily dependent on cellular uptake and phosphorylation efficiency (41). Clinically, several NRTI resistance pathways remain particularly important. M184V/I confers high-level resistance to lamivudine and emtricitabine, K65R is commonly selected under tenofovir pressure and confers reduced susceptibility to tenofovir, and accumulated thymidine analogue mutations can further compromise NRTI susceptibility when combined with other reverse transcriptase mutations (42–44). Non-nucleoside reverse transcriptase inhibitors NNRTIs inhibit HIV-1 reverse transcriptase (RT) by binding to a specific, non-catalytic hydrophobic pocket known as the non-nucleoside inhibitor binding pocket (NNIBP). This binding site is located approximately 10 Å from the polymerase active site. The interaction induces conformational changes in RT that disrupt its enzymatic function, thereby inhibiting viral DNA synthesis (40, 45). Structural studies have elucidated the mechanism of NNRTI action: the induced conformational shift impairs dNTP binding and inhibits polymerization across different nucleic acid substrates, including dsRNA, RNA-DNA hybrids, and dsDNA, next-generation inhibitors of the DAPY class, such as rilpivirine and doravirine, were designed to retain potency against common NNRTI resistance mutations (46). To date, six NNRTIs have received clinical approval, ranging from first-generation nevirapine to the recently approved doravirine. NNRTIs exhibit high selectivity for HIV-1 RT, showing no activity against HIV-2 RT and generally low cellular toxicity. This intrinsic resistance is mainly due to sequence and structural differences in the HIV-2 NNRTI-binding pocket that impair NNRTI binding (2). However, the structural flexibility of the NNIBP also contributes to a high propensity for the development of drug resistance. Clinically, resistance to first-generation NNRTIs is still commonly associated with key substitutions such as K103N and Y181C, whereas rilpivirine resistance is frequently linked to mutations including E138K, K101E, and L100I. Newer NNRTIs such as doravirine retain improved activity against some common NNRTI-resistant variants, but cross-resistance may still emerge in selected settings, particularly after extensive prior NNRTI exposure (47, 48). Integrase inhibitors The integration of the HIV-1 genome into host chromatin is regulated by cellular cofactors. The viral integrase (IN) interacts with the host protein LEDGF/p75, which facilitates the targeted insertion of viral DNA into transcriptionally active regions of the genome (49). LEDGF/p75 contains an IN-binding domain at its C-terminus, while its N-terminal PWWP domain recognizes histone H3 lysine 36 trimethylation (H3K36me3) to mediate chromatin association (50, 51). Studies indicate that when LEDGF/p75 is knocked down, its homolog HRP-2 can partially compensate for its function (52). Notably, even upon dual knockout of LEDGF/p75 and HRP-2, HIV-1 integration does not become entirely random, suggesting the involvement of additional cellular factors. Furthermore, disruption of the IN-LEDGF/p75 interaction—either through LEDGF/p75 depletion or via small-molecule inhibitors known as LEDGINs—results in a shift of integration sites toward more inner nuclear compartments (49). These findings further support integrase-centered processes as therapeutically relevant targets. Clinically, the most established integrase-directed agents are integrase strand transfer inhibitors (INSTIs), which block the strand transfer step of viral DNA integration. Resistance to first-generation INSTIs, such as raltegravir and elvitegravir, most commonly follows the Y143, Q148, and N155 pathways, whereas second-generation agents, including dolutegravir, bictegravir, and cabotegravir, generally retain a higher genetic barrier, although mutations such as R263K, G118R, or Q148-pathway variants with accessory substitutions may still emerge under treatment pressure (53, 54). Env inhibitors Env exhibits greater variability than viral enzymes like reverse transcriptase. However, its conformational changes during fusion expose highly conserved functional regions, making it a suitable target for broad-spectrum fusion inhibitors (Table 2). Unlike enzyme inhibitors that must enter the cell, Env inhibitors act at the cell surface. With no human homolog, they offer greater specificity and a favorable safety profile. Table 2Env-directed entry inhibitors (HIV-1).ClassProductsTarget siteStudy endpoints being evaluatedReferences and/or ClinicalTrials.gov registry numbersSingleVRC01CD4bsEfficacy to prevent sexual transmissionNCT02568215; NCT02716675;PGT121.414.LSV3 loopSafety and PK in HIV- and HIV+ adults and exposed infants(133)PGDM1400LSV2 apexSafety and PK in HIV- and HIV+ adults and exposed infants(134)CAP256V2LSV2 apexSafety and PK in HIV- and HIV+ adults and exposed infantsNCT0440896310E8VLSMPERSafety and PK in HIV- and HIV+ adults and exposed infantsNCT03565315;(135)VRC07-523LSCD4bsSafety and PK in HIV- and HIV+ adults and exposed infants(136)N6LS (VH3810109)CD4bsSafety and PK in HIV- and HIV+ adults and exposed infants(137)ComboTeropavimab (3BNC117-LS)+ Zinlirvimab (10-1074-LS) + LenacapavirCD4bs/V3 loopSafety and PK in HIV- and HIV+ adults and exposed infants/Maintenance of suppression as long-acting regimen(77)Teropavimab (3BNC117-LS) + Zinlirvimab (10-1074-LS) regimenCD4bs/V3 loopSafety and PK in HIV- and HIV+ adults and exposed infants/Maintenance of suppression as long-acting regimenNCT0572956810-1074-LS ± 3BNC117-LSV3 loopSafety and PK in HIV- and HIV+ adults and exposed infantsNCT035544083BNC117-LS + 10-1074-LS (RIO)CD4bs/V3 loopAntiviral activity during viremia and analytical treatment interruptionNCT043193673BNC117-LS + 10-1074-LS (A5364)CD4bs/V3 loopAntiviral activity during viremia and analytical treatment interruptionNCT05079451VRC07-523LS + CAP256V2LSCD4bs/V2 apexAntiviral activity during viremia and analytical treatment interruptionNCT05281510VRC07-523LS + PGT121.414.LS + PGDM1400LSCD4bs/V3 loop/V2 apexEfficacy to prevent sexual transmission/Safety and PK in HIV- and HIV+ adults and exposed infantsNCT06812494TMB-365 + TMB-380CD4/CD4bsMaintenance of suppression as long-acting regimen/Safety and PK in HIV- and HIV+ adults and exposed infantsNCT07215468Multi-specific10E8.4/iMab bispecificMPER/CD4 (± CD4bs)Antiviral activity during viremia and analytical treatment interruption/Safety and PK in HIV- and HIV+ adults and exposed infantsNCT05890963SAR441236CD4bs/V2 apex/MPERSafety and PK in HIV- and HIV+ adults and exposed infants/Antiviral activity during viremia and analytical treatment interruptionNCT03705169CAP256J3LSV2 apexSafety and PK in HIV- and HIV+ adults and exposed infantsNCT06585891Gene transferrAAV1-PG9DPV2 apexSafety and PK in HIV- and HIV+ adults and exposed infants(138) Env-directed entry inhibitors (HIV-1). Protein-/peptide-based fusion inhibitors Ibalizumab is a monoclonal antibody targeting the CD4 receptor. It binds to the CD4 D1-D2 junction region without directly blocking the gp120 binding site. This binding induces conformational changes and steric hindrance, preventing HIV-1 from interacting with CD4. Its heavy-chain CDR-H3 region mimics the key CD4 residue Phe43, occupying the conserved hydrophobic pocket on gp120 to effectively inhibit viral attachment. Approved by the FDA in March 2018 for multidrug-resistant (MDR) HIV-1, its Phase III trials demonstrated significant efficacy (55). Although high cost and resistance risk—linked to V5-loop glycan loss—remain challenges, it is a key option for MDR patients (56).Although ibalizumab is currently approved for multidrug-resistant HIV-1, its CD4-directed post-attachment mechanism, rather than direct binding to a variable viral Env epitope, may explain why HIV-2 isolates can remain susceptible in vitro; however, clinical evidence in HIV-2 is still limited (57). Early soluble CD4 showed limited efficacy against primary HIV-1 isolates, dampening interest in decoy-receptor strategies. However, studies on CD4–gp120 interaction revealed that CD4 binds gp120 via its Phe43 residue, which inserts into a conserved cavity between the inner and outer domains of gp120 (45). This led to the design of CD4-mimetic miniproteins, such as M48U12, which accurately mimic CD4’s gp120-binding properties. Their ability to engage the Phe43 cavity enables potent viral inhibition at low concentrations. The formation of the gp41 six-helix bundle structure represents a critical step in HIV-1 infection (58, 59) This mechanism has enabled the development of several peptide-based inhibitors. Enfuvirtide (T-20), derived from the gp41 HR2 region, was the first fusion inhibitor approved by the FDA. It functions by competitively binding to the HR1 domain, thereby preventing the formation of the six-helix bundle (60). Importantly, enfuvirtide should not be directly extrapolated to HIV-2, because HIV-2 shows markedly reduced susceptibility to this fusion inhibitor. This difference is thought to result from natural sequence variation in the gp41 heptad-repeat target region, which can weaken inhibitor-target interactions and reduce the ability of T-20 to block six-helix bundle formation (2). However, its clinical application is constrained by the need for refrigeration, twice-daily subcutaneous administration, and a tendency to induce drug resistance (61). In contrast, Albuvirtide (FB006M), an HR2 peptide derivative approved in China, has been modified with maleimidopropionic acid to enable binding to human serum albumin. This modification not only significantly enhances its resistance to proteolytic degradation but also extends its half-life to approximately ten times that of enfuvirtide (62), indicating a more favorable clinical application profile. Small-molecule fusion inhibitors CCR5 serves as a key therapeutic target, with the CCR5Δ32 mutation conferring natural resistance to HIV-1 infection. Maraviroc, approved by the FDA in 2007, specifically binds to the CCR5 transmembrane domain and competitively disrupts gp120 engagement, thereby inhibiting viral entry. Because maraviroc is active only against CCR5-tropic HIV-1, tropism testing is mandatory before prescription to confirm the absence of CXCR4-using or dual/mixed-tropic virus (63). For HIV-2, maraviroc may be relevant only for R5-tropic viruses. In vitro studies suggest that HIV-2 R5 isolates can remain susceptible to maraviroc, but the required inhibitory concentrations may be higher than those for HIV-1, and current clinical evidence remains limited (2). High-throughput screening identified NBD-11021, an optimized analog of the CD4-mimetic NBD-556, with improved antiviral activity and no enhancement of infection in CD4-negative/CCR5-positive cells. Another class is represented by fostemsavir (BMS-663068), a prodrug of the active attachment inhibitor temsavir, which binds directly to gp120 near the CD4-binding site and prevents the conformational changes required for viral attachment. Fostemsavir was approved in 2020 for heavily treatment-experienced adults with multidrug-resistant HIV-1 (38, 64). Another class, represented by BMS analogs such as BMS-663068 (approved in 2018 for multidrug-resistant HIV-1), binds to a pocket near the CD4-binding site and blocks gp120 conformational changes required for viral attachment (38, 65, 66). The hydrophobic pocket formed by HR1 helices in gp41 has been exploited for inhibitor design. ADS-J1, identified via computational docking, shows inhibitory activity at low micromolar levels (67). Similarly, 5M038 inhibits viral fusion in the micromolar range. Other candidates such as NB-2, NB-64, and derivatives including A12 and NB-293 require further mechanistic validation. The membrane-proximal external region (MPER) of gp41 is a conserved epitope recognized by broadly neutralizing antibodies such as 2F5, 4E10, Z13e1, 10E8 and DH511 (68). The small molecule S2C3, a dequalinium derivative served as MPER-targeting compound, broadly inhibits HIV-1, HIV-2 and SIV entry (69). Structural studies using NMR on MPER-TMD in bicelles confirmed that S2C3 binds to a hydrophobic pocket formed by residues from adjacent MPER protomers (69). S2C3 stabilizes the prefusion conformation of Env, preventing CD4-induced conformational changes and blocking soluble CD4 binding to cell-surface Env. These findings highlight the potential of MPER-targeting compounds as novel fusion inhibitors (69). Current therapeutic strategies and challenges in HIV-1 management Significant advances in HIV-1 treatment have transformed AIDS from a fatal disease into a manageable chronic condition (70). The current standard of care is highly active antiretroviral therapy, which typically combines multiple drug classes, including nucleoside reverse transcriptase inhibitors (Tenofovir, Lamivudine, Abacavir), non-nucleoside reverse transcriptase inhibitors (Rilpivirine), and integrase strand transfer inhibitors (Dolutegravir) (71, 72). This combination effectively suppresses viral replication, restores immune function, and prolongs life expectancy (Figure 2). HIV-1 replication cycle and the indication of drugs target structural proteins. Upon entering the target cell, reverse transcriptase (RT) transcribes genomic RNA into a reverse transcription complex (RTC). Through IN processing of viral DNA ends, a proviral integration complex (PIC) is generated, which can integrate endogenous DNA prepared by reverse transcription into the DNA. After nuclear entry, the provirus serves as a template for transcription, producing mRNAs that are used to translate viral proteins and assemble with viral proteins into the viral genome. Subsequently, budding occurs, releasing mature HIV-1 virus particles. Recent innovations have further optimized treatment paradigms, particularly through the development of long-acting treatment strategies. Cabotegravir plus rilpivirine provides a maintenance option for virologically suppressed individuals and has shown durable efficacy through 96 and 152 weeks in ATLAS-2M (73, 74). Lenacapavir, a long-acting capsid inhibitor administered every 6 months, has also shown sustained antiviral activity in heavily treatment-experienced individuals with multidrug-resistant HIV-1 when combined with an optimized background regimen (75, 76). Investigational regimens combining lenacapavir with broadly neutralizing antibodies have also shown promise, although they remain under clinical evaluation (77). Despite these advances, drug resistance remains a major clinical challenge and is closely linked to long-term treatment success. Baseline genotypic resistance testing remains important for identifying transmitted resistance, while resistance testing at virologic failure is essential for distinguishing true resistance from suboptimal adherence and for guiding regimen modification (78, 79). Persistent low-level viraemia should not be overlooked because it may indicate emerging resistance or adherence problems (80). By contrast, non-suppressible viraemia may arise from clonally expanded infected cells without evidence of ongoing viral evolution (81). When plasma HIV-1 RNA levels are too low for successful RNA genotyping, proviral HIV-1 DNA genotyping may provide complementary information, although its interpretation requires caution because archived, defective, or hypermutated sequences can be detected (82). The therapeutic arsenal continues to expand with novel agents, including post-attachment inhibitor (Ibalizumab) targeting the viral envelope, new capsid inhibitors (Lenacapavir), and improved fixed-dose combinations (Biktarvy), all contributing to enhanced treatment adherence and patient quality of life (75, 83, 84). A major obstacle to curing HIV-1 is the establishment of a latent viral reservoir. Following initial infection, the HIV-1 genome integrates into the host cell DNA. While the immune system rapidly clears most infected cells, a small fraction enters a state of latency. In these cells, the integrated provirus remains transcriptionally silent, does not produce viral proteins, and thereby evades immune detection, allowing the infected cells to persist long-term (85–88). These latently infected cells, residing in tissues such as the central nervous system and gut-associated lymphoid tissue, constitute a stable reservoir that is not eliminated by current antiretroviral therapy and is considered the primary barrier to an HIV-1 cure (89–91). Current cure strategies primarily focus on targeting this reservoir. Two major therapeutic approaches are under investigation. One approach is latency reversal followed by clearance of reactivated cells, in which latency-reversing agents (LRAs), such as histone deacetylase inhibitors and PKC agonists, are used to reactivate viral gene expression in latently infected cells. Representative LRA classes include histone deacetylase inhibitors (HDACis), such as vorinostat and panobinostat, and protein kinase C (PKC) agonists, such as bryostatin and ingenol-derived compounds, which promote HIV transcription through distinct epigenetic or signaling mechanisms (92, 93). This approach is intended to expose infected cells to the immune system and may be combined with immune-based interventions, including broadly neutralizing antibodies, to enhance clearance of reactivated cells, although the ability of current LRAs to reduce the reservoir in vivo remains limited (94, 95). Conversely, another approach is durable proviral silencing, which seeks to maintain deep latency or long-term viral silencing using epigenetic modifiers such as dCA, thereby maintaining the provirus in a transcriptionally inactive state and preventing future reactivation (96, 97). A representative agent in this context is the Tat inhibitor didehydro-cortistatin A (dCA), which suppresses Tat-dependent transcription and promotes a more stable silencing state, thereby reducing the likelihood of future viral reactivation (98, 99). Cell and gene therapies have emerged as a pivotal direction in HIV-1 cure research, focusing primarily on CRISPR-based gene editing and CCR5 gene modification. Editing the CCR5 gene using tools like CRISPR-Cas9 aims to disrupt this coreceptor and block viral entry into host cells (96, 100, 101). This approach is supported by the cases of the “Berlin patient” and “London patient,” who achieved sustained HIV-1 remission following hematopoietic stem cell transplantation from donors with a natural CCR5-Δ32 mutation. While such a procedure can confer complete resistance to CCR5-tropic HIV-1 strains, its applicability is limited. It is ineffective against CXCR4-tropic viruses and carries significant risks associated with allogeneic hematopoietic stem cell transplantation (HSCT) and prolonged immunosuppression, precluding its widespread use (102–105). Current gene therapy strategies are evolving towards greater diversity. One avenue involves the development of CAR-T cells engineered to specifically recognize and clear HIV-1-infected cells. Another utilizes novel delivery systems to enable the sustained in vivo expression of antiviral agents, such as broadly neutralizing antibodies and CD4 mimetics (106–109). The most advanced strategy involves using gene-editing tools like CRISPR-Cas9 to directly target and excise the integrated provirus. However, this approach faces significant challenges related to target specificity, sequence heterogeneity of the virus, and potential off-target effects (110–114). The application of CAR-T cell therapy for HIV-1 presents unique considerations. During suppressive antiretroviral therapy (ART), viral antigen levels are often too low to drive adequate CAR-T cell activation and expansion. Researchers are investigating strategies to overcome this, including analytical treatment interruption to increase antigen exposure or the use of more potent latency-reversing agents to enhance viral protein expression (115–118). Recent studies in non-human primates suggest that novel adjuvants can effectively expand CAR-T cells even under conditions of low antigen burden, offering a promising direction for optimizing this therapeutic modality. Collectively, these advances are propelling HIV-1 gene therapy from proof-of-concept towards potential clinical translation (119). While combination antiretroviral therapy (cART) effectively suppresses plasma viral loads below detection limits, its principal limitation is rapid viral rebound upon treatment cessation (120–122). To address this, strategies include strengthening drug resistance monitoring to guide individualized therapy. The use of newer agents with high genetic barriers to resistance, such as the integrase inhibitor dolutegravir and the capsid inhibitor lenacapavir, can reduce the risk of resistance development. Furthermore, optimized combination regimens (Tenofovir + Lamivudine + Dolutegravir) help overcome cross-resistance and minimize the accumulation of resistance mutations (123, 124). In parallel, vaccine-related approaches remain an important area of future development and are discussed further in the following section, particularly in the context of next-generation immunogen design and mRNA-based platforms (76, 125–127). Future research directions and perspectives While combination antiretroviral therapy (cART) has profoundly improved the life expectancy and quality of life for people living with HIV, significant challenges remain. These include the persistence of viral reservoirs, the rising threat of drug resistance, and the long-term toxicity associated with lifelong therapy. This review outlines several promising directions for future research and therapeutic development. This involves targeting key viral lifecycle proteins, such as CA, IN, and RT, to develop new inhibitors that overcome existing drug resistance. This includes optimizing broadly neutralizing antibodies (bNAbs)—using structural biology to improve their potency and breadth against diverse HIV-1 strains and exploring their combination with immunomodulators. Furthermore, developing long-acting sustained-release formulations can reduce dosing frequency and improve patient adherence. For CAR-T/TCR-T cell therapies, it is necessary to refine T-cell engineering techniques to enable durable recognition and clearance of latently infected cells while protecting the engineered cells from HIV-1 infection. For CRISPR/Cas9 gene-editing technology, enhancing its precision in targeting integrated proviral DNA or host dependency factors (e.g., CCR5) is crucial to achieve the goal of reservoir elimination. Combining cART with immunotherapy and gene therapy may enhance overall treatment efficacy. Concurrently, advancing personalized precision medicine—tailoring combination regimens based on individual viral reservoir characteristics and immune status—is key to improving the likelihood of a cure. Building on the success of COVID-19 vaccines, developing preventive or therapeutic HIV-1 mRNA vaccines to induce stronger humoral and cellular immune responses is a promising avenue. Research into nanodelivery systems to improve the delivery efficiency of drugs or gene-editing tools to viral reservoir sites (e.g., the brain, gut-associated lymphoid tissue) is also critical. Discussion This narrative review summarizes the critical roles of HIV-1 structural proteins and corresponding therapeutic targeting strategies. The structural proteins Gag, Pol, and Env play indispensable roles in the viral replication cycle, and their precise molecular mechanisms provide vital targets for antiviral drug design. Although existing antiretroviral drugs have achieved notable success in suppressing viral replication, persistent issues remain concerning drug resistance and therapeutic precision. Future advancements necessitate a multidisciplinary approach, integrating progress from molecular biology, immunology, genetic engineering, and clinical medicine. While achieving a complete sterilizing cure for HIV-1 remains a formidable challenge, the continuous breakthroughs in novel therapies—such as long-acting antibodies, gene editing, and immune modulation—make the prospect of a functional cure (long-term viral control without lifelong medication) an increasingly attainable goal in the field of HIV-1 treatment.